Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of MIRCERA is substantial. |
Clinical Added Value
| no clinical added value |
MIRCERA offers no improvement in actual benefit (level V) compared to the other
erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease. |
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
XmKGR4B20rwHphSj
